Fibrinolytic and antibiotic treatment of prosthetic vascular graft infections in a novel rat model

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Fibrinolytic and antibiotic treatment of prosthetic vascular graft infections in a novel rat model. / Johansen, Mikkel Illemann; Rahbek, Søren Jensen; Jensen-Fangel, Søren; Minero, Gabriel Antonio S.; Jensen, Louise Kruse; Larsen, Ole Halfdan; Erikstrup, Lise Tornvig; Seefeldt, Anders Marthinsen; Østergaard, Lars; Meyer, Rikke Louise; Jørgensen, Nis Pedersen.

I: PLoS ONE, Bind 18, e0287671, 2023.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Johansen, MI, Rahbek, SJ, Jensen-Fangel, S, Minero, GAS, Jensen, LK, Larsen, OH, Erikstrup, LT, Seefeldt, AM, Østergaard, L, Meyer, RL & Jørgensen, NP 2023, 'Fibrinolytic and antibiotic treatment of prosthetic vascular graft infections in a novel rat model', PLoS ONE, bind 18, e0287671. https://doi.org/10.1371/journal.pone.0287671

APA

Johansen, M. I., Rahbek, S. J., Jensen-Fangel, S., Minero, G. A. S., Jensen, L. K., Larsen, O. H., Erikstrup, L. T., Seefeldt, A. M., Østergaard, L., Meyer, R. L., & Jørgensen, N. P. (2023). Fibrinolytic and antibiotic treatment of prosthetic vascular graft infections in a novel rat model. PLoS ONE, 18, [e0287671]. https://doi.org/10.1371/journal.pone.0287671

Vancouver

Johansen MI, Rahbek SJ, Jensen-Fangel S, Minero GAS, Jensen LK, Larsen OH o.a. Fibrinolytic and antibiotic treatment of prosthetic vascular graft infections in a novel rat model. PLoS ONE. 2023;18. e0287671. https://doi.org/10.1371/journal.pone.0287671

Author

Johansen, Mikkel Illemann ; Rahbek, Søren Jensen ; Jensen-Fangel, Søren ; Minero, Gabriel Antonio S. ; Jensen, Louise Kruse ; Larsen, Ole Halfdan ; Erikstrup, Lise Tornvig ; Seefeldt, Anders Marthinsen ; Østergaard, Lars ; Meyer, Rikke Louise ; Jørgensen, Nis Pedersen. / Fibrinolytic and antibiotic treatment of prosthetic vascular graft infections in a novel rat model. I: PLoS ONE. 2023 ; Bind 18.

Bibtex

@article{dfae0e6b89804b23a73241966a2cddb3,
title = "Fibrinolytic and antibiotic treatment of prosthetic vascular graft infections in a novel rat model",
abstract = "Objectives We developed a rat model of prosthetic vascular graft infection to assess, whether the fibrinolytic tissue plasminogen activator (tPA) could increase the efficacy of antibiotic therapy. Materials and methods Rats were implanted a polyethylene graft in the common carotid artery, pre-inoculated with approx. 6 log10 colony forming units (CFU) of methicillin resistant Staphylococcus aureus. Ten days after surgery, rats were randomized to either: 0.9% NaCl (n = 8), vancomycin (n = 8), vancomycin + tPA (n = 8), vancomycin + rifampicin (n = 18) or vancomycin + rifampicin + tPA (n = 18). Treatment duration was seven days. Approximately 36 hours after the end of treatment, the rats were euthanized, and grafts and organs were harvested for CFU enumeration. Results All animals in the control group had significantly higher CFU at the time of euthanization compared to bacterial load found on the grafts prior to inoculation (6.45 vs. 4.36 mean log10 CFU/mL, p = 0.0011), and both the procedure and infection were well tolerated. Vancomycin and rifampicin treatment were superior to monotherapy with vancomycin, as it lead to a marked decrease in median bacterial load on the grafts (3.50 vs. 6.56 log10 CFU/ mL, p = 0.0016). The addition of tPA to vancomycin and rifampicin combination treatment did not show a further decrease in bacterial load (4.078 vs. 3.50 log10 CFU/mL, p = 0.26). The cure rate was 16% in the vancomycin + rifampicin group vs. 37.5% cure rate in the.",
author = "Johansen, {Mikkel Illemann} and Rahbek, {S{\o}ren Jensen} and S{\o}ren Jensen-Fangel and Minero, {Gabriel Antonio S.} and Jensen, {Louise Kruse} and Larsen, {Ole Halfdan} and Erikstrup, {Lise Tornvig} and Seefeldt, {Anders Marthinsen} and Lars {\O}stergaard and Meyer, {Rikke Louise} and J{\o}rgensen, {Nis Pedersen}",
note = "Publisher Copyright: {\textcopyright} 2023 Johansen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.",
year = "2023",
doi = "10.1371/journal.pone.0287671",
language = "English",
volume = "18",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",

}

RIS

TY - JOUR

T1 - Fibrinolytic and antibiotic treatment of prosthetic vascular graft infections in a novel rat model

AU - Johansen, Mikkel Illemann

AU - Rahbek, Søren Jensen

AU - Jensen-Fangel, Søren

AU - Minero, Gabriel Antonio S.

AU - Jensen, Louise Kruse

AU - Larsen, Ole Halfdan

AU - Erikstrup, Lise Tornvig

AU - Seefeldt, Anders Marthinsen

AU - Østergaard, Lars

AU - Meyer, Rikke Louise

AU - Jørgensen, Nis Pedersen

N1 - Publisher Copyright: © 2023 Johansen et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

PY - 2023

Y1 - 2023

N2 - Objectives We developed a rat model of prosthetic vascular graft infection to assess, whether the fibrinolytic tissue plasminogen activator (tPA) could increase the efficacy of antibiotic therapy. Materials and methods Rats were implanted a polyethylene graft in the common carotid artery, pre-inoculated with approx. 6 log10 colony forming units (CFU) of methicillin resistant Staphylococcus aureus. Ten days after surgery, rats were randomized to either: 0.9% NaCl (n = 8), vancomycin (n = 8), vancomycin + tPA (n = 8), vancomycin + rifampicin (n = 18) or vancomycin + rifampicin + tPA (n = 18). Treatment duration was seven days. Approximately 36 hours after the end of treatment, the rats were euthanized, and grafts and organs were harvested for CFU enumeration. Results All animals in the control group had significantly higher CFU at the time of euthanization compared to bacterial load found on the grafts prior to inoculation (6.45 vs. 4.36 mean log10 CFU/mL, p = 0.0011), and both the procedure and infection were well tolerated. Vancomycin and rifampicin treatment were superior to monotherapy with vancomycin, as it lead to a marked decrease in median bacterial load on the grafts (3.50 vs. 6.56 log10 CFU/ mL, p = 0.0016). The addition of tPA to vancomycin and rifampicin combination treatment did not show a further decrease in bacterial load (4.078 vs. 3.50 log10 CFU/mL, p = 0.26). The cure rate was 16% in the vancomycin + rifampicin group vs. 37.5% cure rate in the.

AB - Objectives We developed a rat model of prosthetic vascular graft infection to assess, whether the fibrinolytic tissue plasminogen activator (tPA) could increase the efficacy of antibiotic therapy. Materials and methods Rats were implanted a polyethylene graft in the common carotid artery, pre-inoculated with approx. 6 log10 colony forming units (CFU) of methicillin resistant Staphylococcus aureus. Ten days after surgery, rats were randomized to either: 0.9% NaCl (n = 8), vancomycin (n = 8), vancomycin + tPA (n = 8), vancomycin + rifampicin (n = 18) or vancomycin + rifampicin + tPA (n = 18). Treatment duration was seven days. Approximately 36 hours after the end of treatment, the rats were euthanized, and grafts and organs were harvested for CFU enumeration. Results All animals in the control group had significantly higher CFU at the time of euthanization compared to bacterial load found on the grafts prior to inoculation (6.45 vs. 4.36 mean log10 CFU/mL, p = 0.0011), and both the procedure and infection were well tolerated. Vancomycin and rifampicin treatment were superior to monotherapy with vancomycin, as it lead to a marked decrease in median bacterial load on the grafts (3.50 vs. 6.56 log10 CFU/ mL, p = 0.0016). The addition of tPA to vancomycin and rifampicin combination treatment did not show a further decrease in bacterial load (4.078 vs. 3.50 log10 CFU/mL, p = 0.26). The cure rate was 16% in the vancomycin + rifampicin group vs. 37.5% cure rate in the.

U2 - 10.1371/journal.pone.0287671

DO - 10.1371/journal.pone.0287671

M3 - Journal article

C2 - 37463137

AN - SCOPUS:85165518219

VL - 18

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

M1 - e0287671

ER -

ID: 365822195